CDK4/6i通过准E2F1- MCM2/5路径来逆转PARPi电阻
Yujie Feng1,2, Miao Fu1, Bowen Zheng1,2,3
1Xiamen Key Laboratory for Tumor Metastasis, Cancer Research Center, School of Medicine, Xiamen University, Xiamen, China.
NPJ precision oncology
|March 7, 2026
概括
微染色体维护蛋白2和5 (MCM2/5) 在卵巢癌中驱动对多 (ADP-ribose) 聚合酶抑制剂 (PARPis) 的耐药性. 将PARPis与CDK4/6抑制剂结合起来,使瘤对治疗重新敏感.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 多 (ADP-ribose) 聚合酶抑制剂 (PARPis) 在卵巢癌 (OC) 治疗中至关重要.
- 与niraparib一样对PARPis的治疗耐药性是OC中的一个重要的临床障碍.
- 了解新的抵抗机制对于改善患者的治疗结果至关重要.
研究的目的:
- 研究微染色体维护蛋白2和5 (MCM2/5) 在卵巢癌中介于尼拉巴里布耐药性的作用.
- 为了阐明驱动抗性细胞MCM2/5上调的分子通路.
- 评估针对MCM2/5或其调节通路的治疗潜力,并与PARPis.
主要方法:
- RNA测序 (RNA-seq) 用于识别耐尼拉巴里布 (NirR) OC 细胞中差异表达的基因.
- 同免疫沉以评估MCM2/5复杂相互作用.
- 对MCM2/5进行基因操纵 (敲除和过度表达),以确定功能效应.
- 药理上抑制CDK4/6通路的作用.
- 卵巢癌的体外和体内临床前模型.
主要成果:
- 耐尼拉巴的OC细胞表现出显著上调的MCM2和MCM5表达.
- 增强的MCM2/5相互作用与增加的增殖和同源重组修复相关.
- MCM2/5 knockdown使耐尼拉巴里布的抗性细胞重新敏感;过度表达赋予了耐药性.
- MCM2/5上调是由E2F1转录因子驱动的,由CDK4/6-RB通路激活.
- 联合抑制CDK4/6和niraparib可以协同抑制NirR瘤的生长.
结论:
- MCM2/5复合体是卵巢癌中PARPi耐药性的关键调解者.
- 通过CDK4/6-RB通路通过E2F1对MCM2/5的转录调节是一个关键的抵抗机制.
- 将PARPis与CDK4/6抑制剂结合起来,是一个有前途的治疗策略,可以克服OC中的PARPi耐药性.
相关概念视频
Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Negative Regulator Molecules
38.7K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.7K
M-Cdk Drives Transition Into Mitosis
6.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
DNA Damage can Stall the Cell Cycle
10.3K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.3K
DNA Damage Can Stall the Cell Cycle
3.3K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.3K
Positive Regulator Molecules
7.0K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
7.0K


